[Mid-term prognostic value of plasma heavy-chain myosin in thrombolysed myocardial infarction]

K Bendjelid1, P Messner, J M Stordeur

  • 1Service de Cardiologie, Hôpital Arnaud De Villeneuve, CHU de Montpellier, 34295 Montpellier.

Annales De Cardiologie Et D'Angeiologie
|January 31, 2003
PubMed

Insights

An unusual plasma myosin release pattern after myocardial infarction predicts medium-term heart failure and coronary instability. This simple assay identifies high-risk patients early.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Myocardial Infarction Research

Context:

  • Myocardial infarction (MI) management requires accurate prognostic tools.
  • Plasma myosin assays offer a novel method for assessing infarction extent during the acute phase.
  • Prognostic value of plasma myosin release kinetics remains understudied compared to serum assays.

Purpose:

  • To evaluate the prognostic value of plasma myosin heavy chain assay kinetics in predicting medium-term outcomes after acute myocardial infarction.
  • To compare the predictive power of plasma myosin assay with traditional methods for assessing infarction extent.
  • To identify patients at high risk for heart failure and coronary insufficiency post-MI.

Summary:

  • A study followed 40 patients for two years post-MI, correlating initial plasma myosin assay results with clinical outcomes.
  • An unusual (complex) plasma myosin release kinetic was found to predict medium-term heart failure (p=0.04) and coronary insufficiency (p=0.02).
  • Five assays over 10 days can identify high-risk patients with complex release kinetics and an area under the curve > 10.470 µL U/L (p=0.043).

Impact:

  • This research highlights a simple, accessible method for early identification of high-risk MI patients.
  • The findings suggest that plasma myosin kinetics can guide intensified monitoring and treatment strategies.
  • Early risk stratification using plasma myosin assays may improve patient outcomes and reduce healthcare costs.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...